Intuitive Surgical, Inc. (ISRG) reported stronger-than-expected Q2 results, topping both earnings and revenue estimates. The beat was attributable to strong growth in da Vinci procedures and system placements, driven by a rebound in robotic procedures that were deferred due to the COVID-19 pandemic.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shares of the manufacturer of robotic products designed for minimally invasive surgery have gained 39% over the past year.
The company reported adjusted earnings of $3.92 per share, beating analysts’ expectations of $3.06 per share. Revenues of $1.46 billion exceeded the consensus estimate of $1.26 billion.
Meanwhile, revenues jumped 72% on a year-over-year basis, implying a 2-year compound annual growth rate (CAGR) of 15% from 2019. The company reported earnings of $1.11 per share in the prior-year period. (See ISRG stock charts on TipRanks)
During the quarter, 328 da Vinci Surgical Systems were shipped, reflecting an increase of 84%, versus 178 systems shipped in the prior-year quarter.
Intuitive CEO Gary Guthart commented, “We are pleased with our second quarter procedure growth and financial results, which reflect both the demand for high-quality minimally invasive procedures as well as a return to surgeries deferred during the pandemic.”
Following the upbeat Q2 results, Stifel Nicolaus analyst Rick Wise increased the price target from $1,060 to $1,100 (16.4% upside potential) and reiterated a Buy rating on the stock.
Wise said, “Recording yet another exceptionally-robust quarterly-performance, Intuitive 2Q results outperformed Stifel/Consensus estimates on all key metrics: Sales, EPS, procedure volume growth, and system placements.”
He further added, “Encouragingly, the outperformance pushed ISRG 2021 procedure growth guidance to +27%-30% from +22%-26%. All this prompts us to move our numbers higher for 2H21 and beyond, as detailed in our model below.”
Consensus among analysts is a Moderate Buy based on 7 Buys and 8 Holds. The average Intuitive Surgical price target of $988.07 implies 4.6% upside potential to current levels.
ISRG scores a “Perfect 10” on TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations.
Related News:
Dover Soars 6.7% on Q2 Revenue Beat and Raised Guidance
HAL Beats on Q2 Earnings; Shares Soar 3.7%
Cognizant to Snap up TQS Integration